CMS launched a voluntary Medicare payment model designed to expand coverage for GLP‑1 weight‑loss drugs. The agency framed the program as a pilot to test payment and access pathways for expensive incretin therapies, aiming to lower patient costs and evaluate outcomes under Medicare. The move follows sustained price and utilization debates and signals a regulatory push to integrate GLP‑1s into public payor programs. Stakeholders should watch enrollment criteria, reimbursement structure, and evidence requirements that will shape commercial adoption and manufacturer pricing strategies.